


Outpatient Treatment Options for COVID-19 with Mild to Moderate Symptoms (Age 12+)



Outpatient Treatment Options for COVID-19

	Nirmatrelvir-ritonavir [Paxlovid]	Bebtelovimab (Monoclonal Antibodies)	Remdesivir	Molnupiravir [Lagevrio]
Approval/Availability Status	Granted EUA COVID-19 Therapeutic Locator	Granted EUA	FDA Approved	Granted EUA COVID-19 Therapeutic Locator
Dosing	Nirmatrelvir 300mg (two 150mg tabs) + ritonavir 100mg (one 100mg tab) BID x 5 days (total of 30 tabs) For eGFR ≥ 30 to < 60 mL/min: Nirmatrelvir 150mg (one 150mg tab) + ritonavir 100mg (one 100mg tab) BID x 5 days (total of 20 pills)	Bebtelovimab 175mg IV once	200mg IV on day 1, 100mg IV on days 2-3	800mg (four 200mg tabs) BID x 5 days (total of 40 tabs)
Eligibility	12+ At risk for severe disease	12+ At risk for severe disease	12+ At risk for severe disease	18+ At risk for severe disease
Timing of Initiation of Medication	Symptom onset ≤ 5 days	Symptom onset ≤ 7 days	Symptom onset ≤ 7 days	Symptom onset ≤ 5 days
Contraindications/Special Considerations	<ul style="list-style-type: none"> Hypersensitivity to ritonavir/any component Co-administration with drugs highly dependent on CYP3A eGFR < 30 mL/min 	<ul style="list-style-type: none"> History of anaphylaxis to bebtelovimab/any component 	<ul style="list-style-type: none"> Hypersensitivity to remdesivir/any component eGFR <30 mL/min: Manufacturer does not recommend use; however, benefits may outweigh risks; significant toxicity with a short duration of therapy is unlikely 	<ul style="list-style-type: none"> Pregnancy Contraceptive considerations*
Drug Interactions	Contraindications with astemizole, depirdil, fusidic acid, neratinib, rivaroxaban, salmeterol, terfenadine, vardenafil, venetoclax, voriconazole <ul style="list-style-type: none"> Check ALL drug interactions 	Postpone vaccination for 90 days after monoclonal products for treatment	Chloroquine, CYP3A4 inducers, hydroxychloroquine	Cladribine
Mechanism of Action	Protease inhibitor	Binds with virus spike protein	Inhibits viral replication	Induces error in viral RNA replication
Reported Effectiveness Reduction Hospitalization	88% for hospitalization; 99% for death	85% for hospitalization	87% for hospitalization	30% for hospitalization

*Patients who may become pregnant should use reliable contraception correctly and consistently during therapy and for 4 days after the last dose of Molnupiravir. Males with partners who may become pregnant should also use effective contraception during therapy and for at least 3 months after the last Molnupiravir dose.